All experimental models of GVHD explored so far have utilized either genetic or pharmacological blocking of IL-6, and little is therefore known about the relative contributions of trans- versus cis-/classical IL-6 signaling in these settings. This evidence concerns the gene IL6 and graft versus host disease.